A 2026 open-label feasibility trial involving 5 Parkinson’s disease patients found that app-randomized levodopa timing was associated with a mean 4.4-point improvement on the Unified Parkinson’s Disease Rating Scale, but the signal missed conventional statistical significance at p = 0.063.1 The narrow conclusion is feasibility: this was a dosing experiment that justified a blinded controlled …
Sinemet is a pharmaceutical drug engineered by Merck that combines Carbidopa (a peripheral enzymatic inhibitor of DOPA decarboxylase) and Levodopa (an agent that crosses the blood-brain barrier to increase central concentrations of dopamine); hence it is frequently referred to as “Carbidopa-Levodopa.” The drug was initially approved by the U.S. FDA in 1988 for the treatment …
Requip (Ropinirole) is a drug initially approved in 1997 by the United States FDA for the treatment of [early or advanced-stage] idiopathic Parkinson’s disease. In the management of Parkinson’s disease, Requip can be utilized either as: a standalone agent or as an adjunct to L-DOPA. After its initial approval for the attenuation of Parkinson’s symptoms, …